GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Other Current Receivables

ORKA (Oruka Therapeutics) Other Current Receivables : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Other Current Receivables?

Oruka Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.


Oruka Therapeutics Other Current Receivables Historical Data

The historical data trend for Oruka Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Other Current Receivables Chart

Oruka Therapeutics Annual Data
Trend
Other Current Receivables

Oruka Therapeutics Semi-Annual Data
Mar24
Other Current Receivables -

Oruka Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Oruka Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
Address
221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Website
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.